Orion Oyj (HEL:ORNBV)

Market Cap	7.72B
Revenue (ttm)	1.59B
Net Income (ttm)	347.40M
Shares Out	140.69M
EPS (ttm)	2.47
PE Ratio	22.25
Forward PE	19.42
Dividend	1.64 (2.92%)
Ex-Dividend Date	Oct 15, 2025

Volume	24,540
Average Volume	262,276
Open	55.00
Previous Close	55.00
Day's Range	54.60 - 55.10
52-Week Range	36.15 - 57.70
Beta	0.34
RSI	56.10
Earnings Date	Apr 23, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.